NIRS to Monitor Abdominal Tissue Oxygen Saturation in Preterm Infants

Neonatal Disorder Clinical Trial

— CTOM-FIH  

Official title:

NIRS to Monitor Abdominal Tissue Oxygen Saturation in Preterm Infants in an Open Mono-centric Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03706976
• Other study ID #: 2018.7557
• Status: Completed
• Phase: N/A
• Start date: April 30, 2019
• Est. completion date: November 17, 2022

Study information

• Verified date: December 2022
• Source: Carag AG
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The NIRS (near infrared spectroscopy) sensor will be applied to the abdomen of the study population. To ensure good skin contact the sensor will be placed underneath the diaper. If that should not provide enough measurement stability, additional fixation will be given by employing aforementioned flexible bandage routinely employed in neonatal care. Once good skin contact is ensured, the sensor will measure aStO2 (abdominal tissue oxygen saturation) for up to seventy-two hours. The presence of this sensor will not disturb daily clinical activities or medical treatment in any way. Should good skin contact be endangered by movements, clinical interactions or such, the sensor will be removed and re-attached to the infants' abdomen as a consequence.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: November 17, 2022
• Est. primary completion date: November 17, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 35 Weeks

Eligibility

Inclusion Criteria:

• Preterm infants with GA less than 35 0/7 weeks

• Start of measurement earliest at day of life 2 for preterm infants with GA >=30 0/7 weeks and day of life 4 otherwise. The measurement will not start after day of life 5 for all GA.

• Signed Informed consent of the legal representative(s) is received after being informed. It is sufficient, if the consent form is signed by one legal representative, which is in majority of cases either the mother or the father.

• Clinically stable condition. The clinical stability is to be reconfirmed before the start and checked during the measurement.

Exclusion Criteria:

• Injured, hypersensitive or bruised skin present on the belly,

• Existence of clinical instability at any time during the investigation leads to exclusion, if ordered so by the physician entrusted with the investigation,

• Any medical care equipment, e.g. patches, dressing, umbilical arterial or venous catheter, blood supply, etc., prohibiting correct placement of the sensors,

• Dark skin pigmentation or dense hairiness on the belly absorbing too much light in the near infrared region to allow for NIRS,

• Congenital malformations,

• Severe metabolic disorders,

• Early onset sepsis,

• Inability of legal representatives to understand the purpose of the clinical trial due to language barriers such as the insufficient ability to understand the spoken or written language,

• The treatment of newborn jaundice with light during the intended measurement time,

• Previous enrolment into the current study,

• Family members, employees and other dependent persons of the investigator,

• Participation in another study with investigational drug/device within the preceding days and during the present study which may influence aStO2.

Related Conditions & MeSH terms

• Infant, Newborn, Diseases
• Neonatal Disorder

Intervention

Device:
• Tissue Oxygenation Monitoring
The NIRS sensor will be applied to the abdomen of the study population. To ensure good skin contact the sensor will be placed underneath the diaper. If that should not provide enough measurement stability, additional fixation will be given by employing aforementioned flexible bandage routinely employed in neonatal care. Once good skin contact is ensured, the sensor will measure aStO2 for up to seventy-two hours. The presence of this sensor will not disturb daily clinical activities or medical treatment in any way. Should good skin contact be endangered by movements, clinical interactions or such, the sensor will be removed and re-attached to the infants' abdomen as a consequence.

Locations

Country	Name	City	State
Switzerland	Universitätsspital Zürich	Zürich	ZH

Sponsors (1)

Lead Sponsor	Collaborator
Carag AG

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Feasibility of aStO2 measurements in all patients	aStO2 values calculated with and without considering the presence of additional absorbers besides haemoglobin.	72 hours
Secondary	Safety of the investigational device assessed by evaluation of adverse events	Evaluation of AEs (Adverse Event) with regard to the investigational device. The safety related to application and use of the NIRS sensors is aimed for.	72 hours